BioSpace News Archive

The Barbara Ann Karmanos Cancer Institute, a leading breast cancer prevention and care provider, has adopted Volpara® Risk Pathways™, a market-leading software program designed to simplify risk assessment and patient management for various cancers, including breast, lung, ovarian, and colorectal cancer.

Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted nine new employees options to purchase a total of 34,000 shares of the Company’s common stock at an exercise price per share of $17.36, which was the closing price on April 10, 2023, and restricted stock units to acquire a total of 15,200 shares of the Company’s common stock.

RegeneRx Biopharmaceuticals, Inc., a clinical-stage drug development company focused on tissue protection, repair, and regeneration, has issued a Letter to Stockholders updating its ongoing operating strategy.

Sanofi has simplified its contractual arrangements relating to the development and commercialization of Beyfortus in the United States.

Airway Therapeutics, Inc. announced it successfully finished the dose escalation portion of its Phase 1b trial of zelpultide alfa for preventive use in very preterm infants at risk for bronchopulmonary dysplasia.

Bexion Pharmaceuticals, Inc. announced that Bexion Pharmaceuticals will be presenting at the Needham Healthcare Conference.

Human Immunology Biosciences announced positive data from two Phase 2 studies of felzartamab, M-PLACE and NewPLACE.

Rockwell Medical, Inc. announced that the Company is exhibiting its hemodialysis concentrates portfolio in Booth #503 at the National Kidney Foundation Spring Clinical Meetings, which will be held April 11-15, 2023 at the Austin Convention Center in Austin, Texas.

SentiAR, Inc. a St. Louis, Missouri based pioneer in using Augmented Reality visualization technology for medical procedures, has closed an $8.5 million Series B financing.

Beactica Therapeutics AB, the Swedish precision oncology company, announced that its LSD1 programme has been selected for a poster presentation at the American Association for Cancer Research’s Annual Meeting 2023.